NCT07026149 - Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 8, 2025

Primary Completion Date

September 1, 2025

Study Completion Date

May 31, 2030

Conditions

Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma

Interventions

DRUG

Apatinib+Camrelizumab+SOX

Apatinib 250mg+Camrelizumab 200mg +S-1, Oxaliplatin, q3w

RADIATION

Preoperative Radiotherapy

Radiotherapy was administered using IMPT or IMRT. The target volume includes the gastric lesion, and regional lymph nodes. A regimen of 41.4 Gy in 23 fractions is preferred.

Trial Locations (1)

200025

RECRUITING

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai

All Listed Sponsors

lead

Ruijin Hospital

OTHER